At the time of writing, iBio Inc [IBIO] stock is trading at $1.6, up 3.23%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IBIO shares have gain 32.23% over the last week, with a monthly amount glided 91.87%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
iBio Inc [NASDAQ: IBIO] stock has seen the most recent analyst activity on October 21, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $5. Previously, Leerink Partners started tracking the stock with Outperform rating on October 17, 2025, and set its price target to $2. On May 28, 2024, Chardan Capital Markets initiated with a Buy rating and assigned a price target of $5 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $1.50 on November 29, 2021. Cantor Fitzgerald initiated its recommendation with an Overweight and recommended $3 as its price target on January 22, 2021. Alliance Global Partners started tracking with a Buy rating for this stock on June 26, 2020, and assigned it a price target of $2.55.
For the past year, the stock price of iBio Inc fluctuated between $0.56 and $6.89. Currently, Wall Street analysts expect the stock to reach $2 within the next 12 months. iBio Inc [NASDAQ: IBIO] shares were valued at $1.6 at the most recent close of the market. An investor can expect a potential return of 25.0% based on the average IBIO price forecast.
Analyzing the IBIO fundamentals
According to iBio Inc [NASDAQ:IBIO], the company’s sales were 0.40M for trailing twelve months, which represents an 14.29% jump. Gross Profit Margin for this corporation currently stands at 2.98% with Operating Profit Margin at -44.83%, Pretax Profit Margin comes in at -43.89%, and Net Profit Margin reading is -55.98%. To continue investigating profitability, this company’s Return on Assets is posted at -1.1, Equity is -1.3 and Total Capital is -1.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4900 points at the first support level, and at 1.3800 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6800, and for the 2nd resistance point, it is at 1.7600.
Ratios To Look Out For
It is important to note that iBio Inc [NASDAQ:IBIO] has a current ratio of 1.59. As well, the Quick Ratio is 1.59, while the Cash Ratio is 0.92. Considering the valuation of this stock, the price to sales ratio is 81.02, the price to book ratio is 2.08.
Transactions by insiders
Recent insider trading involved Duran Felipe, Chief Financial Officer, that happened on Jan 10 ’25 when 9191.0 shares were purchased. Brenner Martin completed a deal on Jan 10 ’25 to buy 9191.0 shares. Meanwhile, Chief Legal Officer Banjak Marc bought 9191.0 shares on Jan 10 ’25.
